TG Therapeutics, Inc. (TGTX)
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
TGTX jumps after preliminary 2025 sales beat guidance. Its bullish 2026 revenue target and multiple Briumvi pipeline milestones also draw attention.
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TG Therapeutics: What Wall Street Isn't Telling You
TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.
Is the Options Market Predicting a Spike in TG Therapeutics Stock?
Investors need to pay close attention to TGTX stock based on the movements in the options market lately.
TG Therapeutics: Concerns About Slowing Growth And New Competition
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing
TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneous formulation of Briumvi to become available, with a readout from clinical work possible in late 2026 or early 2027. Kyverna Therapeutics's KYV-101 is emerging as a potential competitor to TGTX's Azer-cel in Multiple Sclerosis, although initial KYV-101 data is from a handful of patients.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows
TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven by clinical data, increased prescriber adoption, and a growing anti-CD20 MS therapy market. A subcutaneous version of Briumvi is in Phase 3 trials, potentially doubling TGTX's market opportunity if approved and launched by 2028.
